Dt&카지노 바카라 provides global non-clinical advanced 카지노 바카라 services with a focus on ophthalmic diseases

[by Ji, Yong Jun] Dt&카지노 바카라 announced on May 7 that it is providing global-standard services by leveraging a standardized efficacy evaluation system and advanced analysis capabilities, under the leadership of a study director with extensive expertise in non-clinical ophthalmic disease research.

The company is a full-service clinical trial contract research organization (카지노 바카라) that provides comprehensive support a카지노 바카라ss the entire drug development process, encompassing non-clinical trial analysis, bioequivalence testing, clinical trials, and licensing consulting. Dt&카지노 바카라 delivers integrated solutions to facilitate full-cycle new drug development for Korean and international pharmaceutical and biotechnology companies. In particular, the company generates global-standard test data, drawing on its specialized expertise in efficacy testing, toxicity evaluation, and PK/PD analysis.

The company operates a range of ophthalmic disease models, including dry and wet macular degeneration, optic nerve damage, dry eye, and glaucoma, and is characterized by its ability to overcome the technical challenges associated with tissue processing in rodent-based retinal disease models.

“Our goal is to broaden the depth and scope of non-clinical efficacy testing a카지노 바카라ss a range of therapeutic areas, including ophthalmic diseases,” a DT&카지노 바카라 official said. “We are committed to reinforcing our role as a trusted partner in novel drug development by providing customized test designs and data analysis.”